Enhanced induction of human WT1-specific cytotoxic T lymphocytes with a 9-mer WT1 peptide modified at HLA-A*2402-binding residues

Cancer Immunology, Immunotherapy

Volumn 51, Issue 11-12, 2002, Pages 614-620

  Tsuboi, Akihiro ^a   Oka, Yoshihiro ^a   Udaka, Keiko ^c   Murakami, Masaki ^a   Masuda, Tomoki ^a   Nakano, Akiko ^b   Nakajima, Hiroko ^b   Yasukawa, Masaki ^d   Hiraki, Akio ^e   Oji, Yusuke ^b   Kawakami, Manabu ^a   Hosen, Naoki ^a   Fujioka, Tatsuya ^a   Wu, Fei ^a   Taniguchi, Yuki ^a   Nishida, Sumiyuki ^a   Asada, Momotaro ^a   Ogawa, Hiroyasu ^a   Kawase, Ichiro ^a   Sugiyama, Haruo ^b  

^a OSAKA UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

^b OSAKA UNIVERSITY MEDICAL SCHOOL   (Japan)

^c KYOTO UNIVERSITY   (Japan)

^d EHIME UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^e NATIONAL SANYO HOSPITAL   (Japan)

Author keywords

Cancer immunotherapy; Cytotoxic T lymphocyte; Wilms' tumor gene; WT1

Indexed keywords

CYSTEINYLTYROSYLTHREONYLTRYPTOPHYLASPARAGINYLGLUTAMYLMETHIONYLASPARAGINYLLE UCINE; HLA A ANTIGEN; PROTEIN; UNCLASSIFIED DRUG; WT1 PROTEIN;

AMINO ACID SUBSTITUTION; ARTICLE; BINDING AFFINITY; CANCER CELL CULTURE; CANCER IMMUNOTHERAPY; CELL KILLING; COMPARATIVE STUDY; CONTROLLED STUDY; CYTOTOXIC T LYMPHOCYTE; GENE EXPRESSION; HUMAN; HUMAN CELL; IMMUNOGENICITY; LEUKEMIA CELL; LUNG CANCER; MONONUCLEAR CELL; NEPHROBLASTOMA; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN INDUCTION; PROTEIN MODIFICATION; PROTEIN MOTIF; TUMOR CELL DESTRUCTION;

HLA-A ANTIGENS; HUMANS; IMMUNOTHERAPY; NEOPLASMS; PEPTIDE FRAGMENTS; T-LYMPHOCYTES, CYTOTOXIC; TUMOR CELLS, CULTURED; WT1 PROTEINS;

EID: 0036451819     PISSN: 03407004     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00262-002-0328-9     Document Type: Article

References (32)

1. Theobald M, Biggs J, Hernandez J, Lustgarten J, Labadie C, Sherman LA (1997) Tolerance to p53 by A2.1-restricted cytotoxic T lymphocytes. J Exp Med 185:833
2. Vierboom MP, Nijman HW, Offringa R, van der Voort EI, van Hall T, van den Broek L, Fleuren GJ, Kenemans P, Kast WM, Melief CJ (1997) Tumor eradication by wild-type p53-specific cytotoxic T lymphocytes. J Exp Med 186:695
3. Cibotti R, Kanellopoulos JM, Cabaniols JP, Halle-Panenko O, Kosmatopoulos K, Sercarz E, Kourilsky P (1992) Tolerance to a self-protein involves its immunodominant but does not involve its subdominant determinants. Proc Natl Acad Sci USA 89:416
4. Rosenberg SA, Yang JC, Schwartzentruber DJ, Hwu P, Marincola FM, Topalian SL, Restifo NP, Dudley ME, Schwarz SL, Spiess PJ, Wunderlich JR, Parkhurst MR,Kawakami Y, Seipp CA, Einhorn JH, White DE (1998) Immunologic and therapeutic evaluation of a synthetic peptide vaccine for the treatment of patients with metastatic melanoma. Nat Med 4:321
5. Sette A, Vitiello A, Reherman B, Fowler P, Nayersina R, Kast WM, Melief CJ, Oseroff C, Yuan L, Ruppert J, Sidney J, del Guercio MF, Southwood S, Kubo RT, Chesnut RW, Grey HM, Chisari FV (1994) The relationship between class I binding affinity and immunogenicity of potential cytotoxic T cell epitopes. J Immunol 153:5586
6. Lipford GB, Bauer S, Wagner H, Heeg K (1995) In vivo CTL induction with point-substituted ovalbumin peptides: Immunogenicity correlates with peptide-induced MHC class I stability. Vaccine 13:313
7. Oka Y, Udaka K, Tsuboi A, Elisseeva OA, Ogawa H, Aozasa K, Kishimoto T, Sugiyama H (2000) Cancer immunotherapy targeting Wilms' tumor gene WT1 product. J Immunol 164:1873
8. Gaiger A, Reese V, Disis ML, Cheever MA (2000) Immunity to WT1 in the animal model and in patients with acute myeloid leukemia. Blood 96:1480
9. Tsuboi A, Oka Y, Ogawa H, Elisseeva OA, Li H, Kawasaki K, Aozasa K, Kishimoto T, Udaka K, Sugiyama H (2000) Cytotoxic T-lymphocyte responses elicited to Wilms' tumor gene WT1 product by DNA vaccination. J Clin Immunol 20:195
10. Oka Y, Elisseeva OA, Tsuboi A, Ogawa H, Tamaki H, Li H, Oji Y, Kim EH, Soma T, Asada M, Ueda K, Maruya E, Saji H, Kishimoto T, Udaka K, Sugiyama H (2000) Human cytotoxic T-lymphocyte responses specific for peptides of the wild-type Wilms' tumor gene (WT1) product. Immunogenetics 51:99
11. Gao L, Bellantuono I, Elsasser A, Marley SB, Gordon MY, Goldman JM, StaussHJ (2000) Selective elimination of leukemic CD34(+) progenitor cells by cytotoxic T lymphocytes specific for WT1. Blood 95:2198
12. Ohminami H, Yasukawa M, Fujita S (2000) HLA class I-restricted lysis of leukemia cells by a CD8(+) cytotoxicT-lymphocyte clone specific for WT1 peptide. Blood 95:286
13. Takaki T, Hiraki A, Uenaka A, Gomi S, Itoh K, Udono H, Shibuya A, Tsuji T, Sekiguchi S, Nakayama E (1998) Variable expression on lung cancer cell lines of HLA- A2-binding MAGE-3 peptide recognized by cytotoxic T lymphocytes. Int J Oncol 12:1103
14. Zeh HJ 3rd, Leder GH, Lotze MT, Salter RD, Tector M, Stuber G, Modrow S, Storkus WJ (1994) Flow-cytometric determination of peptide-class I complex formation. Identification of p53 peptides that bind to HLA-A2. Hum Immunol 39:79
15. Tahara T, Yang SY, Khan R, Abish S, Hammerling GJ, Hammerling U (1990) HLA antibody responses in HLA class I transgenic mice. Immunogenetics 32:351
16. Kawakami Y, Rosenberg SA (1995) Cloning of a new gene encoding an antigen recognized by melanoma-specific HLA-A24-restricted tumor-infiltrating lymphocytes. J Immunol 154:5944
17. Udaka K, Wiesmuller KH, Kienle S, Jung G, Tamamura H, Yamagishi H, Okumura K, Walden P, Suto T, Kawasaki T (2000) An automated prediction of MHC class I-binding peptides based on positional scanning with peptide libraries. Immunogenetics 51:816
18. Parkhurst MR, Salgaller ML, Southwood S, Robbins PF, Sette A, Rosenberg SA, Kawakami Y (1996) Improved induction of melanoma-reactive CTL with peptides from the melanoma antigen gp100 modified at HLA-A*0201-binding residues. J Immunol 157:2539
19. van der Burg SH, Visseren MJ, Brandt RM, Kast WM, Melief CJ (1996) Immunogenicity of peptides bound to MHC class I molecules depends on the MHC-peptide complex stability. J Immunol 156:3308
20. Maier R, Falk K, Rotzschke O, Maier B, Gnau V, Stevanovic S, Jung G, Rammensee HG, Meyerhans A (1994) Peptide motifs of HLA-A3, -A24, and -B7 molecules as determined by pool sequencing. Immunogenetics 40:306
21. Valmori D, Fonteneau JF, Lizana CM, Gervois N, Lienard D, Rimoldi D, Jongeneel V, Jotereau F, Cerottini JC, Romero P (1998) Enhanced generation of specific tumor-reactive CTL in vitro by selected Melan-A/MART-1 immunodominant peptide analogues. J Immunol 160:1750
22. Bakker AB, van der Burg SH, Huijbens RJ, Drijfhout JW, Melief CJ, Adema GJ, Figdor CG (1997) Analogues of CTL epitopes with improved MHC class-I binding capacity elicit anti-melanoma CTL recognizing the wild-type epitope. Int J Cancer 70:302
23. Rosenberg SA, Yang JC, Schwartzentruber DJ, Hwu P, Marincola FM, Topalian SL, Restifo NP, Dudley ME, Schwarz SL, Spiess PJ, Wunderlich JR, Parkhurst MR, Kawakami Y, Seipp CA, Einhorn JH, White DE (1998) Immunologic and therapeutic evaluation of a synthetic peptide vaccine for the treatment of patients with metastatic melanoma. Nat Med 4:321
24. Romero P, Gervois N, Schneider J, Escobar P, Valmori D, Pannetier C, Steinle A, Wolfel T, Lienard D, Brichard V, van Pel A, Jotereau F, Cerottini JC (1997) Cytolytic T lymphocyte recognition of the immunodominant HLA-A*0201-restricted Melan-A/MART-1 antigenic peptide in melanoma. J Immunol 159:2366
25. Call KM, Glaser T, Ito CY, Buckler AJ, Pelletier J, Haber DA, Rose EA, Kral A, Yeger H, Lewis WH, et al (1990) Isolation and characterization of a zinc finger polypeptide gene at the human chromosome 11 Wilms' tumor locus. Cell 60:509
26. Gessler M, Poustka A, Cavenee W, Neve RL, Orkin SH, Bruns GA (1990) Homozygous deletion in Wilms' tumours of a zinc-finger gene identified by chromosome jumping. Nature 343:774
27. Inoue K, Sugiyama H, Ogawa H, Nakagawa M, Yamagami T, Miwa H, Kita K, Hiraoka A, Masaoka T, Nasu K, Kyo T, Dohy H, Nakauchi H, Ishidate T, Akiyama T, Kishimoto T (1994) WT1 as a new prognostic factor and a new marker for the detection of minimal residual disease in acute leukemia. Blood 84:3071
28. Menssen HD, Renkl HJ, Rodeck U, Maurer J, Notter M, Schwartz S, Reinhardt R, Thiel E (1995) Presence of Wilms' tumor gene (wt1) transcripts and the WT1 nuclear protein in the majority of human acute leukemias. Leukemia 9:1060
29. Oji Y, Ogawa H, Tamaki H, Oka Y, Tsuboi A, Kim EH, Soma T, Tatekawa T, Kawakami M, Asada M, Kishimoto T, Sugiyama H (1999) Expression of the Wilms' tumor gene WT1 in solid tumors and its involvement in tumor cell growth. Jpn J Cancer Res 90:194
30. Sugiyama H (2001) Wilms' tumor gene WT1: Its oncogenic function and clinical application. Int J Hematol 73:177
31. Yamagami T, Sugiyama H, Inoue K, Ogawa H, Tatekawa T, Hirata M, Kudoh T, Akiyama T, Murakami A, Maekawa T (1996) Growth inhibition of human leukemic cells by WT1 (Wilms' tumor gene) antisense oligodeoxynucleotides: Implications for the involvement of WT1 in leukemogenesis. Blood 87:2878
32. Tsuboi A, Oka Y, Ogawa H, Elisseeva OA, Tamaki H, Oji Y, Kim EH, Soma T, Tatekawa T, Kawakami M, Kishimoto T, Sugiyama H (1999) Constitutive expression of the Wilms' tumor gene WT1 inhibits the differentiation of myeloid progenitor cells but promotes their proliferation in response to granulocyte-colony stimulating factor (G-CSF). Leuk Res 23:499